

Delivering nationwide solutions for problematic healthcare packaging

Harriet Lewis
 Director Public Affairs and Communications Chiesli Limited
 Speaking on behalf of CiPPPA



1

Problems associated with primary pharmaceutical packaging (PPP)

Complex raw materials, design and manufacturing

- Drugs and materials are often **complex** in structure, are **not recyclable** and pose environmental challenges
- Blisters:** Some are made up of 9 different plastics
- Inhalers:** broad range of materials and pressurised gas
- Injectables:** glass vials, bottles, rubber stopper or tear off aluminium gear

Lack of infrastructure to support circularity

- Labeling requirements and consumer education lacking
- Efforts by organisations currently **siload**
- Chemical recycling methods** such as pyrolysis and microwave technology are still **not as widely adopted**
- Lack of coordination** between producers of circular substances and users

Financial implications

- PPP **can not be collected and treated** as a single mixed polymer waste stream
- Take-back schemes are costly** however there is the potential for valorisation of materials

Complicated regulatory landscape

- "Waste Materials" **cannot be used** in the manufacture of PPP
- Although sustainability in PPP is endorsed by policymakers, current regulatory **infrastructure does not support** circularity in PPP manufacturing
- Regulations influence design, safe handling and waste collection

2

Noticeable shift in industry: nationwide roll-out

Treatment

- Re-use
- Recycle
- Repurpose

Logistics

Reverse logistics and/or collection

User interface

Collection points (Pharmacies/stores)

- Addressing the impacts of packaging and plastics across the product lifecycle, from product design to end-of-life
- Investing to remove problematic plastics & investing in solutions to scale recyclability in collaboration with other stakeholders
- Standardisations across industry to reduce unnecessary plastic packaging and halogenated materials
- Development of Infrastructure to support current PPP take back and the transition to sustainable packaging
- Policymakers to strengthen Extended Producer Responsibility (EPR) schemes
- Consumer education to empower consumers to easily separate packaging materials

3

Where we wish to be

- Provide platform for discussions on packaging circularity** - To build to scale viable solutions. Platform for open-to-peer discussions and action. IDI to oversee the coordination of activities and initiatives
- Spearhead regulatory policies to address carbon emissions** - Improved healthcare commitment to carbon neutrality. Chemical products with lower CO2 footprint (e.g. derived pyrolysis oil). Transparent environmental impact to hold companies and organisations to account. Recycling to prevent PPP ending in landfill.
- Set-up task force through value chain for strategic change** - From design, manufacturing and through to recycling. Task force on the three product streams with sub-streams to oversee regulatory landscape, financial, communication, logistics, legal etc)
- Foster behavioural change** - Educational initiatives to support change in behaviour in all stakeholders (from manufacturers to end users/recyclers)
- Scalable and sustainable incentives for all stakeholders** - Incentives to help companies identify opportunities for reducing waste, lowering energy costs, and improve their reputation and relationship with stakeholders

4

What is needed?

- 1 Understand the landscape**
 - Current and future regs - how much material is being used in total vs disposed.
 - Map in initiatives, available infrastructure, chemical recycling, restrictions.
 - Research consumer behaviours and effect of incentives.
 - Circularity vs repurposing
- 2 Collaborate**
 - Secure the power of collaboration
 - Secure advice and input from experts and resources
- 3 Accessibility**
 - Make it simple, and available with operational efficiency
 - Improves consumer engagement
 - Logistics and geographical spreads
- 4 Transparency**
 - Ensure visibility along the full process
 - Build and maintain credibility and trust with public and policy makers
- 5 Sustainable smart goal setting**
 - Move from short term to business as usual
 - Digitise aspects
 - Smartly measurable outcomes
 - De Facto standards nationwide

5

CiPPPA exemplifies industry-wide collaboration...

CiPPPA is a not-for-profit, action-oriented initiative established in September 2023 to identify solutions that can positively impact current waste streams in the Primary Pharmaceutical Packaging (PPP) sector.

...showcasing best practices and the power of working together to achieve positive impact and systemic change

Core objectives

- Pioneering sustainable practices and standards across PPP industry with a focus on circularity
- Fostering pre-competitive collaboration projects to roll out nationwide
- Unwavering commitment to net zero targets creating sustainable, circular and environmentally responsible future

CiPPPA's intention is to better align and scale actions to increase circularity of PPP

- Eliminate pharmaceutical primary packaging waste materials generated and accumulated along the value chain, starting with three product lines:
 - Blester packs
 - Injectable pens, and
 - Respiratory (inhalers)
- Foster collaboration through a participative platform to ensure delivery of industry-wide solutions

6

CiPPPA's short, medium, and long-term goals...

...to foster pre-competitive collaboration and drive systemic change

Short-term:

- Identify and map existing initiatives and supply chain circularity solutions
- Build operational plans for the action task forces
- Create a monitoring and evaluation framework
- Create CiPPPA Governance and Task Force and its operating procedures and policies
- Recruit members

Mid-term:

Members are collectively supporting several circularity initiatives and solutions including but not limited to the following outcomes:


- Processes that enable collection and curation of consumer and industrial recycling of waste
- Enhanced valorisation of consumer and industrial recycling waste processes
- Standardisation and simplification of design across all PPP formats

Long-term:

- Approved used of recycled content for PPP to reduce waste and increase recycling
- Redesign of PPP
- Regulatory alignment with circularity principles
- Behaviour change

Establish product Action Task Forces that are the driving force of CiPPPA

- Blister
- Inhalers
- Injectables




7

The Action Task Forces

Blister Packs Action Task Force


This collaborative effort aims to drive innovation in blister packaging, seeking solutions that align with sustainability goals and address environmental concerns.



01

Injectables Action Task Force


This group seeks to streamline processes, develop innovative solutions, and navigate regulatory landscapes to promote circularity in injectables.



02


Inhalers Action Task Force

This Task Force is dedicated to improving existing recycling schemes and infrastructure to support circularity in inhaler packaging.



03

CiPPPA's three **Action Task Forces** are catalysts for change, driving innovation and collaboration in PPP



8

Uniting forces for a sustainable future with diverse membership categories across the value chain

1 Steering Committee Member

Serve on the CiPPPA leadership and participate in CiPPPA Action Task Forces

Examples of organisations:

- Pharmaceutical, healthcare and veterinary Companies
- Packaging suppliers and manufacturers for pharmaceuticals
- Contract Research Organisations (CROs)
- Research and development organisations in the pharmaceutical sector
- Clinical research and testing laboratories

2 Alliance Member

Actively engage in plenary sessions and could participate in CiPPPA Action Task Forces of interest

Alliance Task Force:

- Can be members from the Steering Committee without leadership positions
- Can be Pharma or non-Pharma
- Actively participate in any of the three-product Task Forces

Eligibility


- Open to all organisations in the PPP value chain
- Join CiPPPA as an Alliance member and contribute as accordance to your business model
- Must be signed up to at least one solution/task force

3 Technical Advisory Group

Non-paying members Advise leadership, management of CiPPPA, and task Force on activities.

Examples of organisations:


- Non-profit organisations
- Patient advocacy groups
- Academic institutions
- Knowledge partners
- Regulatory bodies
- Sustainability agencies or initiatives
- Community pharmacies
- Healthcare providers and hospital
- Public health research organisations



9

Join us in shaping a sustainable tomorrow

Subscribe




Eligibility

- Must fulfil eligibility to join alliance
- Must sign the CiPPPA Agreement with TDI Sustainability (PMO Office responsible for the CiPPPA initiative)
- Must be willing to fully commit to the responsibilities and obligations associated with your chosen membership and/or governance role

Contact

Mayam Babba (Multi-stakeholder Manager, PMO)
 mbabba@tdi-sustainability.com



11